NRXN3 Is a Novel Locus for Waist Circumference: A Genome-Wide Association Study from the CHARGE Consortium by Heard-Costa, Nancy L. et al.
Boston University
OpenBU http://open.bu.edu
Department of Medicine MED: Medicine Papers
2009-6-26
NRXN3 Is a Novel Locus for Waist
Circumference: A Genome-Wide
Association Study from the
CHARGE Consortium
Heard-Costa, Nancy L., M. Carola Zillikens, Keri L. Monda, Åsa Johansson, Tamara B.
Harris, Mao Fu, Talin Haritunians, Mary F. Feitosa, Thor Aspelund, Gudny Eiriksdottir,
Melissa Garcia, Lenore J. Launer, Albert V. Smith, Braxton D. Mitchell, Patrick F.
McArdle, Alan R. Shuldiner, Suzette J. Bielinski, Eric Boerwinkle, Fred Brancati, Ellen
W. Demerath, James S. Pankow, Alice M. Arnold, Yii-Der Ida Chen, Nicole L. Glazer,
Barbara McKnight, Bruce M. Psaty, Jerome I. Rotter, Najaf Amin, Harry Campbell, Ulf
Gyllensten, Cristian Pattaro, Peter P. Pramstaller, Igor Rudan, Maksim Struchalin,
Veronique Vitart, Xiaoyi Gao, Aldi Kraja, Michael A. Province, Qunyuan Zhang, Larry
D. Atwood, Josée Dupuis, Joel N. Hirschhorn, Cashell E. Jaquish, Christopher J.
O'Donnell, Ramachandran S. Vasan, Charles C. White, Yurii S. Aulchenko, Karol
Estrada, Albert Hofman, Fernando Rivadeneira, André G. Uitterlinden, Jacqueline C.
M. Witteman, Ben A. Oostra, Robert C. Kaplan, Vilmundur Gudnason, Jeffrey R.
O'Connell, Ingrid B. Borecki, Cornelia M. van Duijn, L. Adrienne Cupples, Caroline S.
Fox, Kari E. North. "NRXN3 Is a Novel Locus for Waist Circumference: A
Genome-Wide Association Study from the CHARGE Consortium" PLoS
Genetics5(6):e1000539. (2009)
https://hdl.handle.net/2144/2962
Boston University
NRXN3 Is a Novel Locus for Waist Circumference: A
Genome-Wide Association Study from the CHARGE
Consortium
Nancy L. Heard-Costa1., M. Carola Zillikens2., Keri L. Monda3., A˚sa Johansson4., Tamara B. Harris5.,
Mao Fu6., Talin Haritunians7., Mary F. Feitosa8., Thor Aspelund9,10, Gudny Eiriksdottir9, Melissa
Garcia5, Lenore J. Launer5, Albert V. Smith9, Braxton D. Mitchell6, Patrick F. McArdle6, Alan R.
Shuldiner6, Suzette J. Bielinski11, Eric Boerwinkle12, Fred Brancati13, Ellen W. Demerath14, James S.
Pankow14, Alice M. Arnold15, Yii-Der Ida Chen7, Nicole L. Glazer16, Barbara McKnight15, Bruce M.
Psaty17, Jerome I. Rotter7, Najaf Amin18, Harry Campbell19, Ulf Gyllensten4, Cristian Pattaro20, Peter P.
Pramstaller20,21,22, Igor Rudan19,23,24, Maksim Struchalin18, Veronique Vitart25, Xiaoyi Gao8, Aldi Kraja8,
Michael A. Province8, Qunyuan Zhang8, Larry D. Atwood1, Jose´e Dupuis26, Joel N. Hirschhorn27,
Cashell E. Jaquish28, Christopher J. O’Donnell29, Ramachandran S. Vasan30,31, Charles C. White26, Yurii S.
Aulchenko18, Karol Estrada2, Albert Hofman18, Fernando Rivadeneira2,18, Andre´ G. Uitterlinden2,18,
Jacqueline C. M. Witteman18, Ben A. Oostra32", Robert C. Kaplan33", Vilmundur Gudnason9,10", Jeffrey R.
O’Connell6", Ingrid B. Borecki8", Cornelia M. van Duijn18", L. Adrienne Cupples26", Caroline S. Fox29,34"*,
Kari E. North3"*
1Department of Neurology, Boston University School of Medicine, Boston, Massachusetts, United States of America, 2Department of Internal Medicine, Erasmus Medical
Center, Rotterdam, The Netherlands, 3Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America,
4Department of Genetics and Pathology, Uppsala University, Uppsala, Sweden, 5 Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program,
National Institute on Aging, Bethesda, Maryland, United States of America, 6Division of Endocrinology, Diabetes, and Nutrition, University of Maryland School of Medicine,
Baltimore, Maryland, United States of America, 7Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 8Department
of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 9Heart Preventive Clinic and Research Institute, Icelandic Heart
Association, Kopavogur, Iceland, 10University of Iceland, Reykjavik, Iceland, 11Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America,
12Human Genetics Center and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas, United States of America, 13Department of
Medicine and Epidemiology, Johns Hopkins University, Baltimore, Maryland, United States of America, 14Division of Epidemiology and Community Health, University of
Minnesota, Minneapolis, MN, United States of America, 15Department of Biostatistics, University of Washington, Seattle, Washington, United States of America,
16Department of Internal Medicine, University of Washington, Seattle, Washington, United States of America, 17Department of Epidemiology, Medicine, & Health
Services, University of Washington, Seattle, Washington, United States of America, 18Department of Epidemiology and Biostatistics, Erasmus University Medical Center,
Rotterdam, The Netherlands, 19Department of Public Health Sciences, University of Edinburgh Medical School, Edinburgh, Scotland, United Kingdom, 20 Institute of
Genetic Medicine, European Academy Bozen/Bolzano,Bolzano, Italy, 21Department of Neurology, University of Lu¨beck, Lu¨beck, Germany, 22Department of Neurology,
Central Regional Hospital, Bolzano, Italy, 23Croatian Centre for Global Health, University of Split Medical School, Split, Croatia, 24 Institute for Clinical Medical Research,
University Hospital ‘‘Sestre Milosrdnice,’’ Zagreb, Croatia, 25Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh, Scotland, United Kingdom,
26Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, United States of America, 27 Program in Genomics and Divisions of
Endocrinology and Genetics, Harvard Medical School, Boston, Massachusetts, United States of America, 28Division of Prevention and Population Sciences, National Heart,
Lung, and Blood Institute, Bethesda, Maryland, United States of America, 29Division of Intramural Research, National Heart, Lung and Blood Institute, Framingham Heart
Study, Framingham, Massachusetts, United States of America, 30 Boston University School of Medicine, Boston, Massachusetts, United States of America, 31 The
Framingham Heart Study, Framingham, Massachusetts, United States of America, 32Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The
Netherlands, 33Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, United States of America, 34Division of
Endocrinology, Metabolism, and Diabetes, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
Abstract
Central abdominal fat is a strong risk factor for diabetes and cardiovascular disease. To identify common variants influencing
central abdominal fat, we conducted a two-stage genome-wide association analysis for waist circumference (WC). In total,
three loci reached genome-wide significance. In stage 1, 31,373 individuals of Caucasian descent from eight cohort studies
confirmed the role of FTO and MC4R and identified one novel locus associated with WC in the neurexin 3 gene [NRXN3
(rs10146997, p = 6.461027)]. The association with NRXN3 was confirmed in stage 2 by combining stage 1 results with those
from 38,641 participants in the GIANT consortium (p = 0.009 in GIANT only, p = 5.361028 for combined analysis, n = 70,014).
Mean WC increase per copy of the G allele was 0.0498 z-score units (0.65 cm). This SNP was also associated with body mass
index (BMI) [p = 7.461026, 0.024 z-score units (0.10 kg/m2) per copy of the G allele] and the risk of obesity (odds ratio 1.13,
95% CI 1.07–1.19; p = 3.261025 per copy of the G allele). The NRXN3 gene has been previously implicated in addiction and
reward behavior, lending further evidence that common forms of obesity may be a central nervous system-mediated
disorder. Our findings establish that common variants in NRXN3 are associated with WC, BMI, and obesity.
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Introduction
Body mass index (BMI) is a commonly used measure of overall
adiposity. However, specific fat depots may confer differential
metabolic risk. In particular, central abdominal fat, as measured
by waist circumference (WC), may be more strongly associated
with the development of metabolic risk factors and cardiovascular
disease as compared with BMI [1–4]. Therefore, understanding
the pathogenesis of central fat distribution may provide further
insight into the relationship between adiposity, cardiometabolic
risk, and cardiovascular disease.
Both genetic and environmental factors have been linked to
obesity [5]. Heritability estimates for BMI and WC range from 30
to 70% in family and twin studies [6], and multiple quantitative
trait loci and candidate genes have been mapped to genes for
central adiposity [5]. Despite strong evidence for an underlying
genetic component, genes for obesity-related traits, particularly
central obesity, have been difficult to identify and replicate.
Early genome-wide association studies (GWAS) identified both
FTO and MC4R as genes related to BMI and WC [7–10]. Many
new loci have been identified in recent obesity related GWAS
studies [11–13]. However, collectively these variants explain only a
small proportion of the variation in adiposity [7–13]. In addition,
no GWAS exist exclusively to identify genes for central fat. Thus,
to identify new variants, we carried out a large-scale meta-analysis
of GWAS from eight studies to detect variants associated with
central body fat distribution.
Methods
Study Samples
Participants for the current analysis were drawn from 8 cohort
studies, including the Age, Gene/Environment Susceptibility-
Reykjavik Study (AGES- Reykjavik Study), the Atherosclerosis
Risk in Communities Study (ARIC), the Cardiovascular Health
Study (CHS), the European Special Population Network consor-
tium (EUROSPAN), the Family Heart Study, the Framingham
Heart Study, Old Order Amish (OOA), and the Rotterdam Study
(RS). These groups comprise the CHARGE (Cohorts for Heart
and Aging Research in Genome Epidemiology) Consortium. All
Author Summary
Obesity is a major health concern worldwide. In the past
two years, genome-wide association studies of DNA
markers known as SNPs (single nucleotide polymorphisms)
have identified two novel genetic factors that may help
scientists better understand why some people may be
more susceptible to obesity. Similarly, this paper describes
results from a large scale genome-wide association
analysis for obesity susceptibility genes that includes
31,373 individuals from 8 separate studies. We uncovered
a new gene influencing waist circumference, the neurexin
3 gene (NRXN3), which has been previously implicated in
studies of addiction and reward behavior. These findings
lend further evidence that our genes may influence our
desire and consumption of food and, in turn, our
susceptibility to obesity.
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participants provided informed consent. Local ethical committees
at each institution approved the individual study protocols. Text
S1 contains details regarding all participating cohorts.
Imputation and Statistical Analysis
Common to all analyses were use of the raw WC measures
and the assumption of an additive model; study specific details
follow. Each study reported an effect allele which was meta-
analyzed consistently across all studies. Results are currently
presented relative to the minor G allele for the NRXN3 SNP.
In all studies except CHS, MACH (version 1.0.15 in Family
Heart, Framingham, EUROSPAN and RS; version 1.0.16 in
ARIC, AGES, and OOA) was used to impute all autosomal
SNPs on the HapMap, using the publicly available phased
haplotypes (release 22, build 36, CEU population) as a
reference panel. In CHS, the program BIMBAM was used
[14]. Details are provided in Table S1 regarding covariates
and trait creation.
In ARIC, Framingham, and RS, sex- and either cohort-specific
or study center-specific residuals were created after adjustment for
age, age-squared, and smoking status. In CHS and Family Heart,
linear regression models were used to adjust for age, age-squared,
sex, smoking, and study center. In AGES, linear regression models
using PLINK v1.04 [15] were used to adjust for age, age-squared,
sex, and smoking. In the OOA the measured genotype mixed
effects model was used adjusting for age, age-squared, sex and
family structure based on the complete 14-generation pedigree as
implemented in ITSNBN [16]. Framingham employed the linear
mixed effect model for continuous traits and the generalized
estimating equations for dichotomous traits in R [17] to account
for family relatedness. In RS, linear regression models were run
using MACH2QTL [18]. In ARIC and EUROSPAN, all
regression models were run using the ProbABEL package from
the ABEL set of programs [19] and in EUROSPAN genomic
control [20] was used to correct standard errors of the effect
estimates for relatedness among individuals. The Family Heart
Study determined the effect of each SNP using linear mixed effects
models to account for the siblings present in the data using SAS.
Principal components calculated using EIGENSTRAT [21]
were adjusted for in the individual studies when significant in
order to account for population substructure.
Meta-Analysis
A weighted z-score approach was used to conduct meta-analyses
with METAL (www.sph.umich.edu/csg/abecasis/metal/). Geno-
mic control correction was applied to each study prior to the full
meta-analysis. P-values less than 4.461027 were considered
genome-wide significant [22].
In Silico Exchange with the GIANT Consortium
In stage 2 of our study, we conducted an in silico exchange of the
results of 48 SNPs with the GIANT consortium. To create our list
of SNPs to exchange, we first selected the top 34 SNPs from
independent loci (defined as SNPs with R2,0.2) from our meta-
analysis of WC, excluding SNPs in known loci for adiposity. An
additional 14 SNPs of independent loci with a p-value,1.061025
from a secondary list that focused on SNPs for WC with
corresponding BMI p-values.0.01 were also included in an
attempt to isolate genes that might be specifically associated with
central fat deposition. Our a priori threshold for replication was a p-
value,0.001 (0.05/48 SNPs) and/or reaching genome-wide
significance in a combined meta-analysis. CHARGE and GIANT
results were then meta-analyzed using METAL.
Results
Table 1 presents descriptive statistics across the 8 cohorts
providing data for the meta-analysis. We had a total sample size of
31,373 individuals of Caucasian descent. Participants were mostly
middle-aged with ages ranging from a mean of 45 to 76 years of
age.
Figure S1 shows the genome-wide association results for WC in
the stage 1 CHARGE-only analysis. The top SNPs for WC were
in the FTO and MC4R genes (Table S3). Figure S2 shows the QQ
plot for our results excluding SNPs in FTO and MC4R. For FTO,
the top SNP was rs1558902 (p = 4.6610219). For MC4R, the top
SNP was rs489693 (p = 3.561027). The top results excluding
SNPs in FTO and MC4R from our stage 1 meta-analysis are shown
in Table 2 along with the stage 2 in silico replication results from
the GIANT consortium; additional meta-analysis results from
CHARGE are presented in Table S3. The lowest p-value on our
list, for SNP rs10146997 in the NRXN3 gene, had a stage 1 meta-
analysis p-value of 6.461027 and was confirmed in 38,641
participants from the GIANT consortium with a p-value of 0.009
and a combined p-value of 5.361028. The NRXN3 SNP was
derived from the list of SNPs associated with WC irrespective of
association with BMI. None of the other SNPs that were
exchanged were confirmed in GIANT. We do note that while
rs10857809 (proxy for rs10857810) in the FAM40A gene had a p-
value of 0.003 in GIANT, the results were not direction-consistent
with CHARGE and therefore did not replicate in the combined
analysis.
Figure 1 presents the genomic region for SNP rs10146997
(intronic) in NRXN3. Table 3 shows detailed results of
rs10146997 in the NRXN3 gene by contributing CHARGE
study and corresponding results appear in the forest plot in
Figure S3; there was no evidence for heterogeneity across the
stage 1 studies (p = 0.64). The minor allele (G) frequency
(MAF) for rs10146997 in our sample ranged from 0.14 in the
OOA to 0.24 in the Croatians; the frequency of the NRXN3
SNP G allele is 0.275, 1.0, 1.0, and 0.35, in Hapmap CEPH,
Han Chinese, Japanese, and Yoruba populations, respectively.
This SNP was genotyped in AGES, CHS, Family Heart
Study, Rotterdam and all EUROSPAN studies, and imputa-
tion scores for the other studies indicated very high quality.
Overall, per copy of the G allele, mean WC was increased
0.0498 z-score units (0.65 cm). Beta coefficients (in z-score
units) were consistently positive in all samples except the ERF
study (b=20.0098; p = 0.86), which is most likely due to
chance. Due to overlap in participants from the Framingham
Heart Study and ARIC with those from the Family Heart
Study, the CHARGE meta-analysis was re-run for the NRXN3
SNP without the Family Heart Study; results were essentially
unchanged (p = 6.661027). Individual study-specific results for
rs10146997 from the studies comprising the GIANT consor-
tium can be found in Table S2.
Within CHARGE we also observed an association of
rs10146997 with BMI (p = 7.461026). Overall, mean BMI was
increased 0.024 z-score units per G allele (0.10 kg/m2). When WC
was additionally adjusted for BMI, the signal was completely
attenuated (0.0065 z-score units per G allele; p = 0.32). The
association of rs10146997 with WC was similar in women and
men and in older and younger individuals (Table 4). After
excluding smoking from the covariate adjustment list, results were
essentially similar. Per copy of the G allele, the odds ratio of having
high WC ($88 cm in women; $102 cm in men) was 1.07 (95%
CI 1.02–1.11; Table 4). Similarly, the odds ratio of obesity was
1.13 (95% CI 1.07–1.19).
NRXN3 and Waist Circumference
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We calculated a risk score of FTO (rs9939609), MC4R
(rs17782313), and NRXN3 with possible scores ranging from 0–6
risk alleles (Figure 2). Across this range, mean WC increased from
92.4 cm among those with 0 risk alleles, to 95.7 cm among those
with 4 or more risk alleles. To put our findings in perspective, per
copy of the effect allele, the NRXN3 SNP resulted in a WC
difference of 0.65 cm; FTO 0.73 cm, and MC4R 0.37 cm.
CHARGE consortium meta-analysis results for BMI can be
found in Table S4; Manhattan and QQ plots for BMI can be
found in Figure S4 and Figure S5, respectively.
Discussion
In a discovery sample of more than 30,000 individuals from
several cohort studies, we identified a novel locus in the NRXN3
gene associated with WC. In combination with data from the
GIANT consortium, the p-value for this finding exceeded our pre-
defined threshold for genome-wide statistical significance. This
SNP was also significantly associated with BMI and obesity. This
gene has previously been associated with addiction and reward
behavior, and is a compelling biologic candidate for obesity. We
also confirmed the significant associations with FTO and MC4R
that have previously been reported.
Although our genome-wide scan was performed for WC, the
NRXN3 SNP was also significantly associated with BMI. In
secondary analyses, the signal for WC was attenuated after
additionally adjusting for BMI, suggesting that this locus is most
likely involved in overall adiposity and not specific to central fat
deposition. Similar observations have been made for FTO [10] and
MC4R [7], highlighting the inter-dependence between different
measures of adiposity and the importance of performing GWAS
on multiple adiposity-related traits.
The small magnitude of the effect size of the NRXN3 variant on
WC is consistent with what has previously been reported for FTO
and MC4R. These findings highlight the need for large sample
sizes in order to facilitate continued gene discovery for obesity-
related traits. In particular, genes that emerge for waist
circumference will most likely be genes for overall adiposity
because of the strong correlation between the two measurements
[22]. More specific measures of visceral abdominal fat depots may
make it possible to isolate genes involved in regional body
composition.
NRXN3 is part of a family of central nervous adhesion molecules
and is highly expressed in the central nervous system. Prior studies
of NRNX3 point towards an important role in alcohol dependence,
cocaine addiction, and illegal substance abuse [23–26]. In
addition, opioid dependence has been linked to the chromosome
14q region [23]. In mice, NRXN3 beta expression was observed in
the globus pallidus when exposed to cocaine [24]. Many of the
neuronal pathways in these sub-cortical regions of the brain in
which NRXN3 is expressed are involved with learning and reward
training [25].
Obesity and addiction may share common neurologic under-
pinnings [26]. Other well-replicated obesity loci, including MC4R,
have also been shown to be associated with centrally-mediated
phenomena including binge eating behavior [11,12,27]. Studies in
mice indicate that FTO expression is particularly pronounced in
regions of the brain known to regulate energy balance [28], and
recent data suggest that variants in the FTO gene may regulate
food intake and selection [29].
Additional research is needed to understand the association of
rs10146997 with the NRXN3 gene and to identify a causal variant.
Since there are no other genes within a distance of more than
several hundred kilobases of this SNP, it is unlikely that a different
gene accounts for this finding. A search of publically available
databases [30–32] did not identify an association between SNPs in
NRXN3 and gene expression.
A relationship between WC and causal variants in the NRXN3
gene may have clinical implications. Obesity is a multifactorial
trait that results from a complex interaction between genes and
environment. The identification of an association between obesity
and variants in a gene that has been associated with substance
abuse suggests that further exploration of the role of this gene in
vulnerability to addiction to food substances should be undertaken.
The strengths of this work include the large discovery sample
size. The effect size was small, and achieving conventional levels of
genome-wide significance required combining data from more
than 70,000 participants in two large consortia. Although the
confirmation with the GIANT consortium is promising, the joint
p-value based on more than 70,000 participants achieved only
borderline genome-wide significance. Our findings warrant the
need for further replication in other ethnic groups.
We identified a SNP at a novel locus in the NRXN3 gene
associated with WC. This gene has previously been implicated in
Table 1. Descriptive statistics across the eight cohorts.
Cohort N Age (years) % Women Current smokers (%) Waist Circ (cm) BMI (kg/m2)
AGES 3172 76.4 (5.4) 58.0 (1840) 12.7 (402) 100.7 (12.1)* 27.1 (4.4)
ARIC 8097 54.3 (5.7) 52.8 (4276) 25.2 (2036) 96.2 (13.4) 27.0 (4.9)
CHS 3213 72.3 (5.4) 60.0 (1942) 11.0 (354) 93.6 (12.6) 26.4 (4.3)
Family Heart Study 855 55.6 (11.0) 51.5 (440) 11.9 (101) 98.6 (13.6) 27.8 (5.1)
Framingham Heart Study 7115 45.2 (10.9) 52.7 (3750) 18.8 (1338) 91.4 (15.0) 26.0 (5.1)
Old Order Amish 1134 49.6 (16.8) 48.4 (549) 9.4 (106) 88.5 (11.4) 27.0 (4.7)
Rotterdam Study 5471 69.0 (8.8) 58.6 (3205) 23.0 (1258) 90.6 (11.2) 26.3 (3.7)
EUROSPAN Consortium
ERF (Dutch) 1239 48.3 (14.7) 60.1 (744) 43.6 (540) 87.0 (13.7) 26.7 (4.7)
CROATIAN 784 56.5 (15.3) 58.6 (459) 27.7 (217) 95.9 (11.8) 27.3 (4.3)
MICROS (South Tyrolean) 293 46.3 (15.6) 59.7 (175) 45.3 (125) 88.5 (13.3) 25.4 (5.4)
Data provided as mean (standard deviation) for continuous and % (n) for dichotomous data.
*N = 3167 for WC by tape measure; mean (SD) of WC measured by computed tomography is 125.9(14.0) cm.
doi:10.1371/journal.pgen.1000539.t001
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Table 2. Top 48 SNPs exchanged with the GIANT Consortium, GIANT p-values, and the combined results.
Marker Chromosome Position CHARGE pvalue GIANT pvalue* COMBINED pvalue Nearest Gene**
rs10146997 14 79014915 6.4E-07 0.009 5.3E-08 NRXN3
rs981113 5 75556684 9.8E-07 0.55 3.4E-03 SV2C
rs7338657 13 62299289 1.1E-06 0.75 4.4E-04 PCDH20
rs6714750 2 136499639 1.9E-06 0.48 2.9E-03 DARS
rs1555967 6 51267954 1.9E-06 0.07 3.3E-06 PKHD1
rs4701252 5 21814911 2.5E-06 0.45 2.3E-06 CDH12
rs4420638 19 50114786 3.6E-06 0.80 3.8E-04 APOC1
rs2365642 1 199501709 4.1E-06 0.79 3.4E-03 PKP1
rs17008958 3 71838178 4.5E-06 0.18 5.7E-05 EIF4E3
rs7932813 11 7664857 4.6E-06 0.09 5.0E-06 OVCH2
rs569406 9 77219165 4.7E-06 0.54 3.7E-04 OSTF1
rs6837818 4 168112 5.2E-06 0.81 1.1E-03 ZNF718
rs17537900 13 42593449 7.3E-06 0.07 2.9E-03 DNAJC15
rs17476669 2 50579975 7.9E-06 0.27 1.1E-04 NRXN1
rs11857639 15 71424825 8.0E-06 0.94 3.8E-04 HCN4
rs3758063 8 87754664 1.2E-05 0.76 5.4E-03 CNGB3
rs804569 20 22099652 1.4E-05 0.29 1.7E-04 FOXA2
rs13002346 2 133761936 1.6E-05 0.78 1.9E-03 NAP5
rs7138803 12 48533735 1.6E-05 0.01 8.0E-07 BCDIN3D
rs17201502 12 48571829 1.7E-05 0.02 4.2E-06 FAIM2
rs154168 5 107078981 1.7E-05 0.86 2.0E-03 EFNA5
rs1324618 9 121107783 1.8E-05 0.62 0.01 DBC1
rs1553754 17 43918706 2.0E-05 0.05 1.2E-05 HOXB1
rs12971184 18 32134683 2.1E-05 0.43 0.03 FHOD3
rs253414 5 74992273 2.3E-05 0.47 8.0E-04 C5orf37
rs309193 19 52317155 2.4E-05 0.20 1.8E-04 C19orf7
rs12457723 18 27981438 2.4E-05 0.14 0.08 RNF138
rs8006194 14 88980606 2.5E-05 0.63 0.01 FOXN3
rs10172766 2 205587746 3.0E-05 0.30 0.01 PARD3B
rs11096633 2 20067535 3.1E-05 0.47 5.2E-04 MATN3
rs8049894 16 75371885 3.1E-05 0.67 1.9E-03 CNTNAP4
rs12148445 15 34703950 3.1E-05 0.60 0.01 C15orf41
rs9829637 3 135638752 3.5E-05 0.10 4.9E-05 ANAPC13
rs7666149 4 41017949 3.7E-05 0.06 2.1E-05 LIMCH1
rs13421140 2 1753016 4.2E-05 0.97 6.1E-03 MYT1L
rs4238692 16 82149934 5.8E-05 0.14 1.4E-04 CDH13
rs17833967 12 13846345 6.0E-05 0.46 1.2E-03 GRIN2B
rs1532206 3 99153367 6.2E-05 0.89 9.2E-03 MINA
rs6723108 2 135196450 6.2E-05 0.27 4.4E-04 TMEM163
rs12704232 7 85640166 7.4E-05 0.61 0.05 GRM3
rs12377679 9 128437576 8.0E-05 0.12 1.1E-04 LMX1B
rs1017643 6 156835825 9.5E-05 0.04 2.6E-05 ARID1B
rs6485438 11 43643194 1.3E-04 0.09 9.7E-05 HSD17B12
rs7116632 11 129452949 1.9E-04 0.74 0.04 APLP2
rs422988 1 4718977 2.4E-04 0.62 3.5E-03 AJAP1
rs5771623 22 47415000 2.9E-04 0.07 0.28 FAM19A5
rs6728666 2 216894986 5.3E-04 0.76 0.02 MARCH4
rs10857810*** 1 110403320 1.8E-04 .003 0.97 FAM40A
*GIANT sample size is 38,641.
**Nearest reference is bolded if SNP is within the reference gene.
***GIANT SNP is proxy rs10857809 (r2 = 0.92).
doi:10.1371/journal.pgen.1000539.t002
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Figure 1. Regional Association Plot for rs10146997 on chromosome 14 in the stage 1 CHARGE-only analysis. The color scheme is red
for strong linkage disequilibrium (LD; r2$0.8), orange for moderate LD (r2$0.5 and,0.8), yellow for weak LD (r2$0.2 and,0.5) and white for limited
or no LD (r2,0.2).
doi:10.1371/journal.pgen.1000539.g001
Table 3. Results per copy of the G allele for rs10146997 by contributing study; beta coefficients expressed as z-scores.
Cohort N MAF (G)
Imputation Quality
Score Beta Coefficient SE p-value
AGES 3170 0.21 Genotyped 0.058 0.031 0.06
ARIC 8097 0.22 0.98 0.032 0.019 0.12
CHS 3213 0.21 Genotyped 0.103 0.030 0.00048
Family Heart Study 855 0.21 Genotyped 0.003 0.055 0.65
Framingham Heart Study 7115 0.20 1.00 0.068 0.022 0.0019
Old Order Amish 1097* 0.14 0.87 0.049 0.073 0.33
Rotterdam Study 5471 0.21 Genotyped 0.042 0.024 0.08
EUROSPAN Consortium
ERF (Dutch) 1241 0.20 Genotyped 20.010 0.052 0.86
Croatia 784 0.24 Genotyped 0.039 0.059 0.52
MICROS (South Tyrolean) 293 0.17 Genotyped 0.057 0.101 0.60
Meta-analysis results 31373 0.21 N/A 0.0498 0.010 6.461027
SE = standard error; MAF = minor allele frequency.
*Sample size reduced from 1134 because smokers excluded due to the low smoking prevalence.
doi:10.1371/journal.pgen.1000539.t003
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Table 4. CHARGE consortium secondary analysis results per copy of the G allele for rs10146997 in 31373 individuals; beta
coefficients expressed as z-scores.
Beta Coefficient SE p-value
Overall 0.0498 0.010 6.461027
Overall without adjusting for smoking 0.0460 0.010 5.661026
Sex stratification
Women 0.0500 0.014 4.761024
Men 0.0427 0.013 0.001
Age stratification
,55 years 0.0520 0.017 0.002
55+ years 0.0560 0.013 7.461026
Odds Ratio 95% CI p-value
WC category*
High WC (women $88 cm, men $102 cm) 1.07 1.02–1.11 0.003
BMI categories**
Overweight (BMI 25 to ,30) 1.03 0.98–1.07 0.250
Obese (BMI$30) 1.13 1.07–1.19 3.261025
*Referent = normal WC category (women ,88 cm; men ,102 cm).
**Referent = normal weight category (BMI 18.5-,25 kg/m2).
doi:10.1371/journal.pgen.1000539.t004
Figure 2. Mean waist circumference by number of risk alleles for FTO, MC4R, and NRXN3. Bars represent standard errors. The panel on the
left represents the distribution of risk alleles in the overall sample.
doi:10.1371/journal.pgen.1000539.g002
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addiction and reward behavior, lending further support to the
concept that obesity, in part, is a centrally-mediated disorder.
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